Table 1 Monoclonal antibodies
From: A review of ocular adverse events of biological anti-TNF drugs
Drug | Etanercept (Enbrel) | Infliximab (Remicade) | Adalimumab (Humira) | Golimumab (Simponi, Simponi Aria) | Certolizumab (Cimzia) |
Structure and mechanism of action | TNFR2 ectodomain fused to IgG1 binds TNF-α and TNF-β | Chimeric murine-human IgG1 that binds TNF-α | Fully humanized IgG1 that binds TNF-α | Fully humanized IgG1 that binds TNF-α | Humanized PEGylated Fab that binds TNF-α |
Indications | RA, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, and juvenile idiopathic arthritis | RA, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, idiopathic pulmonary fibrosis, ulcerative colitis, and Crohn’s disease | RA, psoriatic arthritis, ankylosing spondylitis, spondyloarthritis, juvenile idiopathic arthritis, uveitis (intermediate, posterior, panuveitis), plaque psoriasis, hidradenitis suppurativa, ulcerative colitis, and Crohn’s disease | RA, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis | RA, psoriatic arthritis, ankylosing spondylitis, spondyloarthritis, and Crohn’s disease |
Reported ocular side effects | Uveitis, scleritis, ON, and ocular myositis | Uveitis, ON, and endophthalmitis | Uveitis, ON, endophthalmitis, corneal infiltrates, retinal toxicity, and ophthalmoplegia | ON | ON |